PT - JOURNAL ARTICLE AU - Oscar Brück TI - The Gender Gap in Leading Medical Journals - a Computational Audit AID - 10.1101/2022.12.21.22283801 DP - 2022 Jan 01 TA - medRxiv PG - 2022.12.21.22283801 4099 - http://medrxiv.org/content/early/2022/12/21/2022.12.21.22283801.short 4100 - http://medrxiv.org/content/early/2022/12/21/2022.12.21.22283801.full AB - Background Publication track record can impact careers of researchers. Therefore, monitoring gender representation in medical research is required to achieve equity in academia.Methods We gathered bibliometric data on original research articles published between 2010 and 2019 in The New England Journal of Medicine, Nature Medicine, Journal of the American Medical Association, The BMJ, and The Lancet using the Web of Science indexing database. We associated publication and citation frequency with author gender, count, and institute affiliation, and research keywords.Findings We analyzed 10,558 articles and found that women published and were cited less than men. There were fewer women as senior (24.8%) than leading authors (34.5%, p<0.001). The proportion of female authors varied by country with 9.1% last authors from Austria, 0.9% from Japan, and 0.0% from South Korea. The gender gap decreased longitudinally and faster for last (−24.0 articles/year, p<0.001) than first authors (−14.5 articles/year, p=0.024). The trend varied by country and even increased in China and Israel. Author count was associated with higher citation count (R 0.46, p<0.001) as well as with male first (n=11 vs. n=10, p<0.001) and last authors (n=11 vs. n=10, p<0.001). We also discovered that usage of research keywords varied by gender, and it partly accounted for the difference in citation counts by gender.Interpretation Gender representation has increased both at the leading and senior author levels although with country-specific variability. The study frame can be easily applied to any journal and time period to monitor changes in gender representation in science.Competing Interest StatementO.B. declares no Competing Non-Financial Interests but the following Competing Financial Interests: consultancy fees from Novartis, Sanofi, and Amgen, outside the submitted work.Funding StatementThis study was supported by research grants from the Helsinki University Hospital.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCodes and a 100-row data example are available at https://github.com/obruck/International-Research-Impact. Raw data can be downloaded from Clarivate Web of Science, with instructions provided in the Github repository.